KEAP1 and cholangiocarcinoma: In this study, FOXO3 was found to promote the transcription of KEAP1, and this FOXO3–KEAP1 axis was downregulated with a corresponding hyperactivation of NFR2 in clinical cholangiocarcinoma samples [154].